Caffeine Citrate does not reduce brain injury following inflammation-amplified hypoxia ischaemia or hypoxia ischaemia in the Newborn Piglet Model
There is a need to develop alternative therapies for neonatal encephalopathy (NE) in term babies. Caffeine citrate exposure saw benefit in preclinical models of hypoxia-ischaemia (HI). We assessed the safety and cytoprotective efficacy of caffeine citrate in an inflammation-amplified (IA-HI) and HI newborn piglet model based on the probability of treatment superiority (Pr<sub>(sup)</sub>) of magnetic resonance spectroscopy, amplitude integrated encephalography (aEEG/EEG) and immunohistochemistry outcomes. Eighteen newborn piglets were randomised to saline, 20/10/10 mg/kg or 60/30/30 mg/kg caffeine citrate following IA-HI. A further twenty piglets were randomised to saline or 40/10/10 mg/kg caffeine citrate following HI. Caffeine plasma concentrations were within range following a 20/10/10 mg/kg dosage but were lower than putative target levels following a 40/10/10 mg/kg dosage. Caffeine concentrations exceeded toxic levels following a 60/30/30 mg/kg dosage. Following IA-HI, 20/10/10 or 60/30/30 mg/kg caffeine citrate treatment failed to reduce white matter (WM) (Pr<sub>(sup)</sub> 39.3 %, 52.5 %) and basal ganglia and thalamic (BGT) (Pr<sub>(sup)</sub> 35.0 %, 50.3 %) lactate/N-acetylaspartate (Lac/NAA), preserve the phosphocreatine/exchange phosphate pool (PCr/Epp) ratio (Pr<sub>(sup)</sub> 44.2 %, 62.0 %), or improve aEEG/EEG recovery (Pr<sub>(sup)</sub> 22.4 %, 21.7 %). A 60/30/30 mg/kg dose demonstrated increased cell death, indicating toxicity. Following HI, 40/10/10 mg/kg caffeine citrate treatment failed to reduce WM (Pr<sub>(sup)</sub> 58.3 %) and BGT (Pr<sub>(sup)</sub> 48.0 %) Lac/NAA, preserve the PCr/Epp ratio (Pr<sub>(sup)</sub> 72.8 %), or improve aEEG/EEG recovery (Pr<sub>(sup)</sub> 48.0 %), with seizures more refractory. However, there was a modest benefit in male caffeine-treated piglets following HI. The lack of neuroprotection observed following caffeine citrate treatment after both IA-HI and HI suggests further preclinical studies are required before clinical translation for term babies with NE.
Authors
- Christopher Meehan
- John Barks (ORCID: https://orcid.org/0000-0003-1320-905X)
- George Maple
- Nicola Jayne Robertson (ORCID: https://orcid.org/0000-0002-5783-0828)
- Alison Mintoft
- Ellie Campbell
- Raymand Pang (ORCID: https://orcid.org/0000-0002-2004-6650)
- Kennosuke Tsuda (ORCID: https://orcid.org/0000-0002-7323-5260)
- Alan Bainbridge (ORCID: https://orcid.org/0000-0001-7783-7747)
- Louise Han (ORCID: https://orcid.org/0000-0002-8256-9414)
- Jong Seung Kim (ORCID: https://orcid.org/0000-0003-3477-1172)
- Katie Tucker (ORCID: https://orcid.org/0009-0009-0349-3107)
- Francisco Torrealdea
- Georgina Norris (ORCID: https://orcid.org/0009-0007-9755-6038)
- Ivana d’Angelo (ORCID: https://orcid.org/0000-0003-0444-0444)
Institutions
- University of Michigan (US)
- Royal London Hospital (GB)
- London Women's Clinic (GB)
- UCL Biomedical Research Centre (GB)
- Institute for Reproductive Health (US)
- University College London (GB)
Publication Details
- Journal
- Neuropharmacology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.neuropharm.2025.110763
- Primary Topic
- Neonatal and fetal brain pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00